

What is Claimed is:

B1 Sub 1

1. A method for inhibiting apoptosis of a cell comprising treating the cell with an effective amount of a Receptor Internalization and Degradation (RID) complex.
2. The method of claim 1 wherein the treating step comprises administering to the cell a polynucleotide encoding the RID complex and wherein the RID complex is expressed in the cell.
- Sub B2* 3. The method of claim 2 wherein the polynucleotide comprises a recombinant adenovirus vector.
4. The method of claim 3 wherein the recombinant adenovirus vector is 231-10.
5. The method of claim 3 wherein the cell expresses Fas, TNFR-1, DR3, TRAIL-R1, or TRAIL-R2.
- Sub B3* 6. The method of claim 5 wherein the cell is a leukocyte.
7. The method of claim 5 wherein the cell comprises a transplant tissue.
8. The method of claim 1 wherein the treating step comprises administering the RID complex to the cell.
9. The method of claim 8 wherein the RID complex is administered with a carrier which facilitates delivery of the RID complex into the cell.
10. A method for decreasing apoptosis of target cells in a patient comprising treating the patient with an effective amount of a Receptor Internalization and Degradation (RID) complex.
11. The method of claim 10 wherein the treating step comprises administering to the patient a polynucleotide encoding the RID complex and wherein the polynucleotide is internalized in the target cells and the RID complex is expressed.
- Sub B5* 12. The method of claim 11 wherein the polynucleotide comprises a recombinant adenovirus vector.
13. The method of claim 12 wherein the recombinant adenovirus vector is 231-10.
14. The method of claim 10 wherein the patient suffers from a degenerative disease or an immunodeficiency disease.
15. The method of claim 10 wherein the treating step comprises administering the RID complex to the patient.
16. The method of claim 15 wherein the RID complex is administered with a carrier which facilitates delivery of the RID complex into the cells.
17. A method for decreasing leukocyte apoptosis in a patient comprising:
 - (1) withdrawing leukocytes from the patient,
 - (2) treating the leukocytes with an effective amount of a RID complex, and
 - (3) administering the treated leukocytes to the patient.

18. The method of claim 17 wherein the treating step comprises administering to the leukocytes a polynucleotide encoding the RID complex wherein the RID complex is expressed in the leukocytes.

Sub B7 19. The method of claim 18 wherein the polynucleotide comprises a recombinant adenovirus vector.

20. The method of claim 19 wherein the recombinant adenovirus vector is 231-10.

~~21. The method of claim 17 wherein the treating step comprises administering the RID complex to the leukocytes.~~

~~22. The method of claim 21 wherein the RID complex is administered with a carrier which facilitates delivery of the RID complex into the leukocytes.~~

~~23. A composition comprising a Receptor Internalization and Degradation (RID) complex and a carrier suitable for facilitating delivery of the RID complex into a cell.~~

~~24. A recombinant adenovirus comprising a polynucleotide encoding a Receptor Internalization and Degradation (RID) complex operably linked to a promoter, wherein the adenovirus is replication defective and wherein the polynucleotide is expressed upon infection of a eukaryotic cell with the adenovirus.~~

25. The recombinant adenovirus vector of claim 24 consisting of 231-10.

BEST AVAILABLE COPY